Evidence map›Paper›PMID 41520064›Full record

Observational studyEye (London, England)2026

Early detection of neovascular age-related macular degeneration in the second eye reduces intravitreal treatment burden: FASBAT report 2.

Rachel L W Hanson, Archana Airody, Sobha Sivaprasad, Martin McKibbin, Antony B Morland, Tunde Peto, Usha Chakravarthy, Richard P Gale, FASBAT study group

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rachel L W HansonAcademic Unit of Ophthalmology, York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK.ORCID 0000-0002-2569-9810
Archana AirodyAcademic Unit of Ophthalmology, York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK.
Sobha SivaprasadNIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Martin McKibbinLeeds Teaching Hospital NHS Trust, Leeds, UK.ORCID 0000-0003-4388-243X
Antony B MorlandDepartment of Psychology, University of York, York, UK.
Tunde PetoCentre for Public Health, Queen's University of Belfast, Belfast, UK.ORCID 0000-0001-6265-0381
Usha ChakravarthyCentre for Public Health, Queen's University of Belfast, Belfast, UK.ORCID 0000-0002-2606-3734
Richard P GaleAcademic Unit of Ophthalmology, York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK. Richard.gale@york.ac.uk.ORCID 0009-0006-0213-6253
FASBAT study group

Funding

Novartis | Novartis Pharmaceuticals UK Limited (Novartis UK) OAP030A2401T
6 · The paper itself

Abstract

BACKGROUND/

objectivesTo investigate if early detection of neovascular age-related macular degeneration (nAMD) in the second eye is associated with a reduced number of intravitreal treatments compared with the first eye using data from the EDNA/FASBAT trial. SUBJECTS/

methodsPost-hoc analysis of 117 participants receiving standard clinical care during the FASBAT study. Assessments were at enrolment and at an average of 18.9 (SD = 10.2) and 30.5 (SD = 9.7) months in the first eye. Assessment of the second eye was made at the onset of nAMD (as participants were monitored for conversion) and at 12- and 24-months. The annualised injection rate for first eyes and the actual rate for second eyes are reported alongside visual acuity (VA) and optical coherence tomography (OCT) characteristics.

resultsIn second eyes the annualised number of treatments was lower both in year 1 (second eyes mean = 6.4, SD = 3.4 vs mean = 7.2, SD = 1.9 in first eyes) and in year 2 (second eyes mean = 5.8, SD = 2.9; versus mean = 6.2, SD = 2.7 in first eyes). Second eyes had better VA at the point of conversion to nAMD (mean = 74.1, SD = 9.9) compared with the first eyes at baseline (mean = 55.6, SD = 15.3) which was maintained until 24 months (second eye: mean = 73.6, SD = 9.9; first eye: mean = 53.2, SD = 19.3). Highly reflective material was detected less frequently in second eyes compared to first eyes at clinical visits.

conclusionsCompared to first eyes, early detection of nAMD in the second eye is beneficial in terms of better maintenance of visual acuity, reduced intravitreal treatment burden, and improved anatomical findings after 2 years of treatment.

Indexed as

Angiogenesis InhibitorsWet Macular DegenerationAgedAged, 80 and overBevacizumabEarly DiagnosisFemaleHumansIntravitreal InjectionsMaleRanibizumabTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID41520064
PMCPMC12957419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.